3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neuroendocrine Tumors
15
Paraganglioma
4
Meningioma
4
Carcinoma, Neuroendocrine
4
Pheochromocytoma
3
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Medullary
2
Carcinoid Tumor
2
Somatostatinoma
1
Serotonin Syndrome
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Disease Progression
1
Carcinoma, Merkel Cell
1
Carcinoid Heart Disease
1
Breast Neoplasms
1
Advanced Lung Neuroendocrine Tumor
1
Adenoma, Islet Cell
1
Interventions
pembrolizumab
9
avelumab
9
Nivolumab
8
atezolizumab
4
Specimen Handling
4
durvalumab
3
cemiplimab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Cyclophosphamide
3
Biopsy
3
ALT-803
3
talimogene laherparepvec
2
fludarabine phosphate
2
fludarabine
2
domatinostat
2
Radiosurgery
2
Ipilimumab
2
Cisplatin
2
Carboplatin
2
relatlimab
1
oblimersen
1
lutetium Lu 177 dotatate
1
lenvatinib
1
lanreotide
1
daromun
1
cabozantinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Merkel Cell
×
lutetium Lu 177 dotatate
×
Clear all
NCT05583708
2026-04-22
iPRRT
Weill Medical College of Cornell University
Phase 2
Recruiting
18 enrolled